



CTE Session 1

Technologists Committee / SNMMI

Sunday, October 5, 08:00 – 09:30

Session Title

Tech Guide Launch

Chairpersons

Luísa Roldão Pereira (Maidstone, United Kingdom)

Ângelo Cardoso (Bern, Switzerland)

Programme

08:00 – 08:15 **Agata Pietrzak** (Poznań, Poland) **and Laura Evangelista** (Milan, Italy): Why is it important to talk about Women's Health?

08:15 – 08:45 **Gracinda Costa** (Coimbra, Portugal): Nuclear Medicine role in Endometriosis

08:45 – 09:15 **Oliver Ramsay** (Boston, United States): Promising Radiopharmaceuticals

09:15 – 09:30 **Victoria Rowe** (Brighton, United Kingdom): Radiation Protection Considerations for the Female Worker

Educational Objectives

1. Delve into the importance of investing in Women's Health Diagnostics and Therapeutics, considering historical issues in addressing women's unique health needs, with an emphasis on conditions that predominantly affect women or manifest differently in women.
2. Explore the role of promising radiopharmaceuticals, gaining insight into the value and their applications, including radiopharmaceuticals in Conventional Nuclear Medicine (99mTc-Maraciclatide) and PET (FAPI, FES).
3. Consider Radiation Protection for Female Workers in Nuclear Medicine, promoting discussion of best practices for ensuring safe working for female workers in healthcare settings, including understanding the potential occupational risks of radiation exposure in key stages of their lives (e.g., pregnancy).

Summary

This session offers a comprehensive preview of the content featured in this year's Tech Guide Publication, which looks into the distinctive health considerations for female patients and workers in nuclear medicine settings. As women's health needs differ significantly from men's and have in the past often been scientifically and socially overlooked, this session provides crucial insights into the importance of investing in diagnostics and therapeutics that specifically address conditions that affect women or manifest differently in women.

A key focus of the session is the application of radiopharmaceuticals, such as 99mTc-Maraciclatide, and advanced PET techniques (including, FDG, FAPI and FES), which play (or are expected to play) vital roles in diagnosing and treating women's health conditions like endometriosis, breast cancer, gynaecological cancers, osteoporosis, and other gender-specific diseases. It highlights the nuances of radiopharmaceuticals in women's health, acknowledging that female patients may require distinct approaches due to differences in metabolism and responses.



Additionally, this session examines the occupational risks for female healthcare workers, particularly in relation to radiation exposure. Special attention is given to the challenges faced by pregnant or breastfeeding workers, and those returning to work after parental leave. It emphasises the importance of conducting thorough risk assessments for radiation exposure and manual handling to ensure the health and safety of female staff in these environments.

The multidisciplinary collaboration that shaped this session brings together a range of expert perspectives, offering a well-rounded view of the evolving nature of women's health in the context of medical imaging, diagnostics, and therapeutic interventions. Participants will gain a deeper understanding of the dynamic intersection of patient care and occupational health, with an emphasis on safeguarding both female patients and healthcare workers in these critical areas.

Key Words

Women's health; Endometriosis; Breast; Female worker; Occupational Risk; Radiation Protection